Kyverna Therapeutics(KYTX) - 2024 Q4 - Annual Results

Exhibit 99.1 Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results Accelerating clinical path to commercialization in stiff person syndrome, myasthenia gravis and lupus nephritis Fourth Quarter 2024 Highlights and Recent Business Updates KYV-101: Autologous, fully human CD19 CAR T-cell product candidate, incorporating highly potent CD28 co- stimulation. KYV-101 is currently being evaluated in company-sponsored KYSA trials and investigator- initiated tr ...